@article{
 title = {Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets},
 type = {article},
 year = {2010},
 identifiers = {[object Object]},
 keywords = {80 and over,Adult,Aged,Disease Progression,Disease-Free Su,Humans,Japan,Middle Aged,Neoplastic,Ovarian N,Platinum,Prognosis,Proportiona,Treatment Outcome,administration /&/ dosage,diagnosis/genetics/mortality},
 pages = {e9615},
 volume = {5},
 websites = {http://dx.doi.org/10.1371/journal.pone.0009615},
 institution = {Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.},
 id = {36754df6-08e1-3360-99ba-8515fad53634},
 created = {2012-04-04T15:37:38.000Z},
 file_attached = {false},
 profile_id = {00fd71da-e805-3e9b-bd6d-ce1da66adfce},
 group_id = {65b20e96-92ca-3d76-a4e9-a84ba22c682d},
 last_modified = {2012-04-05T12:40:25.000Z},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 citation_key = {Yoshihara2010},
 source_type = {article},
 abstract = {Advanced-stage ovarian cancer patients are generally treated with platinum/taxane-based chemotherapy after primary debulking surgery. However, there is a wide range of outcomes for individual patients. Therefore, the clinicopathological factors alone are insufficient for predicting prognosis. Our aim is to identify a progression-free survival (PFS)-related molecular profile for predicting survival of patients with advanced-stage serous ovarian cancer.Advanced-stage serous ovarian cancer tissues from 110 Japanese patients who underwent primary surgery and platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays. We selected 88 PFS-related genes by a univariate Cox model (p<0.01) and generated the prognostic index based on 88 PFS-related genes after adjustment of regression coefficients of the respective genes by ridge regression Cox model using 10-fold cross-validation. The prognostic index was independently associated with PFS time compared to other clinical factors in multivariate analysis [hazard ratio (HR), 3.72; 95% confidence interval (CI), 2.66-5.43; p<0.0001]. In an external dataset, multivariate analysis revealed that this prognostic index was significantly correlated with PFS time (HR, 1.54; 95% CI, 1.20-1.98; p = 0.0008). Furthermore, the correlation between the prognostic index and overall survival time was confirmed in the two independent external datasets (log rank test, p = 0.0010 and 0.0008).The prognostic ability of our index based on the 88-gene expression profile in ridge regression Cox hazard model was shown to be independent of other clinical factors in predicting cancer prognosis across two distinct datasets. Further study will be necessary to improve predictive accuracy of the prognostic index toward clinical application for evaluation of the risk of recurrence in patients with advanced-stage serous ovarian cancer.},
 bibtype = {article},
 author = {Yoshihara, Kosuke and Tajima, Atsushi and Yahata, Tetsuro and Kodama, Shoji and Fujiwara, Hiroyuki and Suzuki, Mitsuaki and Onishi, Yoshitaka and Hatae, Masayuki and Sueyoshi, Kazunobu and Fujiwara, Hisaya and Kudo, Yoshiki and Kotera, Kohei and Masuzaki, Hideaki and Tashiro, Hironori and Katabuchi, Hidetaka and Inoue, Ituro and Tanaka, Kenichi},
 journal = {PLoS One},
 number = {3}
}

{"_id":"aqBMy58wGfECuJKsJ","bibbaseid":"yoshihara-tajima-yahata-kodama-fujiwara-suzuki-onishi-hatae-etal-geneexpressionprofileforpredictingsurvivalinadvancedstageserousovariancanceracrosstwoindependentdatasets-2010","downloads":0,"creationDate":"2016-01-19T08:46:40.545Z","title":"Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets","author_short":["Yoshihara, K.","Tajima, A.","Yahata, T.","Kodama, S.","Fujiwara, H.","Suzuki, M.","Onishi, Y.","Hatae, M.","Sueyoshi, K.","Fujiwara, H.","Kudo, Y.","Kotera, K.","Masuzaki, H.","Tashiro, H.","Katabuchi, H.","Inoue, I.","Tanaka, K."],"year":2010,"bibtype":"article","biburl":null,"bibdata":{"title":"Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets","type":"article","year":"2010","identifiers":"[object Object]","keywords":"80 and over,Adult,Aged,Disease Progression,Disease-Free Su,Humans,Japan,Middle Aged,Neoplastic,Ovarian N,Platinum,Prognosis,Proportiona,Treatment Outcome,administration /&/ dosage,diagnosis/genetics/mortality","pages":"e9615","volume":"5","websites":"http://dx.doi.org/10.1371/journal.pone.0009615","institution":"Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.","id":"36754df6-08e1-3360-99ba-8515fad53634","created":"2012-04-04T15:37:38.000Z","file_attached":false,"profile_id":"00fd71da-e805-3e9b-bd6d-ce1da66adfce","group_id":"65b20e96-92ca-3d76-a4e9-a84ba22c682d","last_modified":"2012-04-05T12:40:25.000Z","read":false,"starred":false,"authored":false,"confirmed":"true","hidden":false,"citation_key":"Yoshihara2010","source_type":"article","abstract":"Advanced-stage ovarian cancer patients are generally treated with platinum/taxane-based chemotherapy after primary debulking surgery. However, there is a wide range of outcomes for individual patients. Therefore, the clinicopathological factors alone are insufficient for predicting prognosis. Our aim is to identify a progression-free survival (PFS)-related molecular profile for predicting survival of patients with advanced-stage serous ovarian cancer.Advanced-stage serous ovarian cancer tissues from 110 Japanese patients who underwent primary surgery and platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays. We selected 88 PFS-related genes by a univariate Cox model (p<0.01) and generated the prognostic index based on 88 PFS-related genes after adjustment of regression coefficients of the respective genes by ridge regression Cox model using 10-fold cross-validation. The prognostic index was independently associated with PFS time compared to other clinical factors in multivariate analysis [hazard ratio (HR), 3.72; 95% confidence interval (CI), 2.66-5.43; p<0.0001]. In an external dataset, multivariate analysis revealed that this prognostic index was significantly correlated with PFS time (HR, 1.54; 95% CI, 1.20-1.98; p = 0.0008). Furthermore, the correlation between the prognostic index and overall survival time was confirmed in the two independent external datasets (log rank test, p = 0.0010 and 0.0008).The prognostic ability of our index based on the 88-gene expression profile in ridge regression Cox hazard model was shown to be independent of other clinical factors in predicting cancer prognosis across two distinct datasets. Further study will be necessary to improve predictive accuracy of the prognostic index toward clinical application for evaluation of the risk of recurrence in patients with advanced-stage serous ovarian cancer.","bibtype":"article","author":"Yoshihara, Kosuke and Tajima, Atsushi and Yahata, Tetsuro and Kodama, Shoji and Fujiwara, Hiroyuki and Suzuki, Mitsuaki and Onishi, Yoshitaka and Hatae, Masayuki and Sueyoshi, Kazunobu and Fujiwara, Hisaya and Kudo, Yoshiki and Kotera, Kohei and Masuzaki, Hideaki and Tashiro, Hironori and Katabuchi, Hidetaka and Inoue, Ituro and Tanaka, Kenichi","journal":"PLoS One","number":"3","bibtex":"@article{\n title = {Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets},\n type = {article},\n year = {2010},\n identifiers = {[object Object]},\n keywords = {80 and over,Adult,Aged,Disease Progression,Disease-Free Su,Humans,Japan,Middle Aged,Neoplastic,Ovarian N,Platinum,Prognosis,Proportiona,Treatment Outcome,administration /&/ dosage,diagnosis/genetics/mortality},\n pages = {e9615},\n volume = {5},\n websites = {http://dx.doi.org/10.1371/journal.pone.0009615},\n institution = {Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.},\n id = {36754df6-08e1-3360-99ba-8515fad53634},\n created = {2012-04-04T15:37:38.000Z},\n file_attached = {false},\n profile_id = {00fd71da-e805-3e9b-bd6d-ce1da66adfce},\n group_id = {65b20e96-92ca-3d76-a4e9-a84ba22c682d},\n last_modified = {2012-04-05T12:40:25.000Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n citation_key = {Yoshihara2010},\n source_type = {article},\n abstract = {Advanced-stage ovarian cancer patients are generally treated with platinum/taxane-based chemotherapy after primary debulking surgery. However, there is a wide range of outcomes for individual patients. Therefore, the clinicopathological factors alone are insufficient for predicting prognosis. Our aim is to identify a progression-free survival (PFS)-related molecular profile for predicting survival of patients with advanced-stage serous ovarian cancer.Advanced-stage serous ovarian cancer tissues from 110 Japanese patients who underwent primary surgery and platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays. We selected 88 PFS-related genes by a univariate Cox model (p<0.01) and generated the prognostic index based on 88 PFS-related genes after adjustment of regression coefficients of the respective genes by ridge regression Cox model using 10-fold cross-validation. The prognostic index was independently associated with PFS time compared to other clinical factors in multivariate analysis [hazard ratio (HR), 3.72; 95% confidence interval (CI), 2.66-5.43; p<0.0001]. In an external dataset, multivariate analysis revealed that this prognostic index was significantly correlated with PFS time (HR, 1.54; 95% CI, 1.20-1.98; p = 0.0008). Furthermore, the correlation between the prognostic index and overall survival time was confirmed in the two independent external datasets (log rank test, p = 0.0010 and 0.0008).The prognostic ability of our index based on the 88-gene expression profile in ridge regression Cox hazard model was shown to be independent of other clinical factors in predicting cancer prognosis across two distinct datasets. Further study will be necessary to improve predictive accuracy of the prognostic index toward clinical application for evaluation of the risk of recurrence in patients with advanced-stage serous ovarian cancer.},\n bibtype = {article},\n author = {Yoshihara, Kosuke and Tajima, Atsushi and Yahata, Tetsuro and Kodama, Shoji and Fujiwara, Hiroyuki and Suzuki, Mitsuaki and Onishi, Yoshitaka and Hatae, Masayuki and Sueyoshi, Kazunobu and Fujiwara, Hisaya and Kudo, Yoshiki and Kotera, Kohei and Masuzaki, Hideaki and Tashiro, Hironori and Katabuchi, Hidetaka and Inoue, Ituro and Tanaka, Kenichi},\n journal = {PLoS One},\n number = {3}\n}","author_short":["Yoshihara, K.","Tajima, A.","Yahata, T.","Kodama, S.","Fujiwara, H.","Suzuki, M.","Onishi, Y.","Hatae, M.","Sueyoshi, K.","Fujiwara, H.","Kudo, Y.","Kotera, K.","Masuzaki, H.","Tashiro, H.","Katabuchi, H.","Inoue, I.","Tanaka, K."],"urls":{"Website":"http://dx.doi.org/10.1371/journal.pone.0009615"},"bibbaseid":"yoshihara-tajima-yahata-kodama-fujiwara-suzuki-onishi-hatae-etal-geneexpressionprofileforpredictingsurvivalinadvancedstageserousovariancanceracrosstwoindependentdatasets-2010","role":"author","keyword":["80 and over","Adult","Aged","Disease Progression","Disease-Free Su","Humans","Japan","Middle Aged","Neoplastic","Ovarian N","Platinum","Prognosis","Proportiona","Treatment Outcome","administration /&/ dosage","diagnosis/genetics/mortality"],"downloads":0},"search_terms":["gene","expression","profile","predicting","survival","advanced","stage","serous","ovarian","cancer","two","independent","datasets","yoshihara","tajima","yahata","kodama","fujiwara","suzuki","onishi","hatae","sueyoshi","fujiwara","kudo","kotera","masuzaki","tashiro","katabuchi","inoue","tanaka"],"keywords":["80 and over","adult","aged","disease progression","disease-free su","humans","japan","middle aged","neoplastic","ovarian n","platinum","prognosis","proportiona","treatment outcome","administration /&/ dosage","diagnosis/genetics/mortality"],"authorIDs":[]}